Pharmacy

Your Article Summary

See Latest Articles

Use and cost of erythropoiesis-stimulating agents in patients with cancer
Current Medical Research and Opinion, 06/19/09

Daniel G et al. - Significant differences characterize patterns of use of erythropoiesis-stimulating agents. Duration of therapeutic benefit is an important variable in comparing darbepoetin alfa with epoetin alfa; incorporation of this variable in analyses of costs of therapy may have notable effects on calculated treatment costs. Limitations of the study include the potential for database errors or omissions, lack of detailed disease data, and lack of adjustment for differences in the ages and comorbidities of patients.

Today in Chemotherapy/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Palliative Oncology: Thalidomide
American Journal of Hospice and Palliative Medicine, 10/21/09

Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09

Aspirin use associated with lower colorectal cancer mortality
American Pharmacists Association, 10/14/09

See All of Chemotherapy/Oncology

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09

Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals
QJM: An International Journal of Medicine, 10/16/09

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09

See All of Pharmacoeconomics